Pharmaceutical & Cosmetic Raw Materials Supplier-OCTAGON CHEMICALS LIMITED
Competitive APIs

FDA Approved Injection Grade Bacitracin 1405-87-4

Bacitracin 1405-87-4

FDA Approved Injection Grade Bacitracin is manufactured by growing the bacteria Bacillus subtilis var Tracy in a container of liquid growth medium in our FDA-Audited facility. Over fermentation the bacteria synthesizes the antibiotic and secretes the antibiotic into the medium. Then bacitracin is extracted from the medium by chemical processes.

Injection Grade Bacitracin is composed of a mixture of related compounds with varying degrees of antibacterial activity. Notable fractions include bacitracin A, A1, B, B1, B2, C, D, E, F, G, and X. Bacitracin A has been found to have the most antibacterial activity. Bacitracin B1 and B2 have similar potencies and are approximately 90% as active as bacitracin A. Other bacitracin components including F and X do not appear to be extensively studied.

Injection Grade Bacitracin is a mixture of peptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. These peptides disrupt both gram positive and gram negative bacteria by interfering with cell wall.

Topical Grade Bacitracin is primarily made into ointments (as it is can cause kidney damage when used internally).

Bacitracin can also be used in pure form for those with allergies to the polymyxin B and neomycin components of the combination product.

Bacitracin is also commonly used as an aftercare antibiotic on tattoos and circumcision. It is preferred over combination products such as Neosporin because of its fewer ingredients, which lowers chances of an allergic reaction.

In infants, bacitracin is rarely administered intramuscularly for the treatment of staphylococcal pneumonia and empyema when due to organisms shown susceptible to bacitracin. This use is extremely limited, since bacitracin is nephrotoxic and the concentration of bacitracin in the blood must be followed closely.

Bacitracin has been used to distinguish Streptococcus pyogenes from other "strep" bacteria, with S. pyogenes being sensitive to bacitracin and others resistant. In this case bacitracin is used to distinguish S. pyogenes from other β-hemolytic streptococci.

Bacitracin is also commonly used to distinguish Haemophilus influenzae colonies amongst respiratory flora; since H. influenzae is intrinsically resistant to bacitracin, colonies form within the zone of inhibition.

Bacitracin is synthesised nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not directly involved in its synthesis.

Docs available for Bacitracin/Bacitracina: GMP/USDMF/FDA/COA/MSDS/HPLC